Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Thursday, Pfizer Inc (NYSE:PFE) announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s GSK patents relating to its respiratory syncytial virus (RSV) vaccine. Also Read: UK Chooses ...